Details of the Drug

General Information of Drug (ID: DM6NPUJ)

Drug Name

NLX-P101

Synonyms

RAAV-GAD; STN AAV-GAD gene therapy, Neurologix; Subthalamic nucleus AAV-glutamic acid decarboxylase gene therapy, Neurologix; NLX gene therapy (Parkinson's), Neurologix

Indication

Disease Entry	ICD 11	Status	REF
Parkinson disease	8A00.0	Discontinued in Phase 2	[1]
------------------------------------------------------------------------------------

Cross-matching ID

DrugBank ID: DB05924
TTD ID: D0VT0T

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glutamate decarboxylase (GLUL)	TTURQ2G	GLNA_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Parkinson disease

ICD Disease Classification

8A00.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Glutamate decarboxylase (GLUL)	DTT	GLUL	2.45E-01	-0.23	-0.4

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017938)
2	NLX-P101, an adeno-associated virus gene therapy encoding glutamic acid decarboxylase, for the potential treatment of Parkinson's disease. Curr Opin Investig Drugs. 2010 Jul;11(7):813-22.